bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases & T cell-based immunotherapies. The company’s objective is to develop & bring to market the most advanced products based on the transformative potential of gene therapy to provide patients hope for a better life in the face of limited or no long-term safe & effective treatment options. Headquartered in Cambridge, bluebird bio has operations in the US & Europe.